Sarasola P, Jernigan AD, Walker DK, Castledine J, Smith DG, Rowan TG (2002) Pharmacokinetics
of selamectin following intravenous, oral and topical administration in cats and dogs. J Vet
Pharm Ther 25:265–272
Schaffert D, Wagner E (2008) Gene therapy progress and prospects: synthetic polymer-based
systems. Gene Ther 15:1131–1138
Scheerlinck JP, Greenwood DL (2006) Particulate delivery systems for animal vaccines. Methods
40:118–124
Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der
Valk MA, Robanus-Maandag EC, te Riele HP, Berns, AJM, Borst, P (1994) Disruption of the
mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to
increased sensitivity to drugs. Cell 77:491-502
Schleis SE, LeBlanc AK, Neilsen NR, LeBlanc CJ (2008) Flow cytometric evaluation of multi-
drug resistance proteins on grossly normal canine nodal lymphocyte membranes. Am J Vet Res
69:1310–1315
Schrickx JA, Fink-Gremmels J (2008) Implications of ABC transporters on the disposition of
typical veterinary medicine products. Eur J Pharmacol 585:510–519
Sendelbeck L, Moore D, Urquhart J (1975) Comparative distribution of pilocarpine in ocular
tissues of the rabbit during administration by eyedrop or by membrane-controlled delivery
systems. Am J Ophthalmol 80:274–283
Shao ZJ (2001) Aquaculture pharmaceuticals and biologicals: current perspectives and future
possibilities. Adv Drug Deliv Rev 50:229–243
Simpson BS, Landsberg GM, Reisner IR, Ciribassi JJ, Horwitz D, Houpt KA, Kroll TL, Luescher
A, Moffat KS, Douglass G, Robertson-Plouch C, Veenhuizen MF, Zimmerman A, Clark TP
(2007) Effects of Reconcile 1 (fluoxetine) chewable tablets plus behavior management for
canine separation anxiety. Vet Ther 8:18–31
Smith M, Omidi Y, Gumbleton M (2007) Primary porcine brain microvascular endothelial cells:
biochemical and functional characterisation as a model for drug transport and targeting. J Drug
Target 15:253–268
Smith LJ, KuKanich B, Hogan BK, Brown C, Heath TD, Krugner-Higby LA (2008) Pharmacoki-
netics of a controlled-release liposome-encapsulated hydromorphone administered to healthy
dogs. J Vet Pharmacol Ther 31:415–422
Snowden NJ, Helyar CV, Platt SR, Penderis J (2006) Clinical presentation and management of
moxidectin toxicity in two dogs. J Small Anim Pract 47:620–624
Stanley AC, Buxton D, Innes EA, Huntley JF (2004) Intranasal immunisation with Toxoplasma
gondii tachyzoite antigen encapsulated into PLG microspheres induces humoral and cell-
mediated immunity in sheep. Vaccine 22:3929–3941
Streubel A, Siepmann J, Bodmeier R (2006) Drug delivery to the upper small intestine window
using gastroretentive technologies. Curr Opin Pharmacol 6:501–508
Stride BD, Grant CE, Loe DW, Hipfner DR, Cole SPC, Deeley RG (1997) Pharmacological
characterization of the murine and human orthologs of multidrug-resistance protein in trans-
fected human embryonic kidney cells. Mol Pharmacol 52:344–353
Sun H, Chow Edwin CY, Liu S, Du Y, Sandy PK (2008) The Caco-2 cell monolayer: usefulness
and limitations. Expert Opin Drug Metab Toxicol 4:395–411
Sutton SC (2004) Companion animal physiology and dosage form performance. Adv Drug Del
Rev 56:1383–1398
Tang F, Horie K, Borchardt RT (2002) Are MDCK cells transfected with the human MDR1 gene a
good model of the human intestinal mucosa? Pharm Res 19:765–772
Terasaki T, Ohtsuki S, Hori S, Takanaga H, Nakashima E, Hosoya K-I (2003) New approaches to
in vitromodels of blood-brain barrier drug transport. Drug Discov Today 8:944–954
Thombre AG (2004) Oral delivery of medications to companion animals: palatability considera-
tions. Adv Drug Del Rev 56:1399–1410
Drug Delivery Systems in Domestic Animal Species 111